Connecting Products to Patients Through Precise Commercialization
We are a full service management consulting firm with skills in research, strategy and implementation.
Our research capabilities provide clients with tailored contemporary intelligence on the life sciences industry. Among the types of insights we deliver are: primary and secondary research, advisory boards, seminars, summits, environmental scans, article and white paper development, insights sessions, and custom research efforts with read-outs.
We deliver highly actionable plans that align tightly to brand objectives that are meant to evolve over 1-5 years. We tell clients not to tell us we did a good job on the project or even in the first year, but rather tell us whether the 5 year was a success. It takes knowing the client, knowing the industry and having the vision for what will unfold for both. We have been doing this since 2001.
The best designs aren’t worth anything if the idea cannot be implemented. We build client strategies and solutions with the idea that our clients will implement or manage on their own, but that’s not always possible due to clients skills, bandwidth or time constraints. Blue Fin Group is happy to help. We have robust implementation methodologies that keep commercial teams aligned and focused on execution - even under rapid go-to-market conditions.
Who We Help
Our primary clients are pharmaceutical manufacturers that are either commercializing their first asset or large global firms with products that span Cell and Gene Therapies, Orphan/Rare, Specialty, Primary Care, Vaccines, Biosimilars, and Generics.
Because of our breadth and depth servicing over 300 clients, including 29 of the top 30 pharmaceutical manufacturers many channels such as pharmacies and health plans and vendors such as patient services and data and technology providers, work with us to help them refine business models and messaging.
Pharmaceutical manufacturers struggle with their silos in marketing, market access, field sales, pharmacy and distribution and patient services. This is a legacy from the days of commercializing products in primary care when science was developed for unmet needs, share of voice was what drove demand, patients had simple and affordable copays, product was available at every corner pharmacy and products didn’t need to have elaborate support services. In the world of Specialty, none of this is the case. Patient populations are small. Costs of products are higher. Payer barriers are intense. Physical access is limited and patients need special services that pharmacy cannot afford to provide.
Healthplans, pharmacies, group purchasing organizations, distributors and providers sometimes struggle to understand how their models can help or hinder patient access. These pharmaceutical channels come to Blue Fin Group to understand an insiders view of pharma so they can refine their models and messaging.
Similar to channels, services providers such as data and technology providers, logistics companies, and patient services vendors all want to understand how their service can work to benefit the pharmaceutical manufacturer and patient experience. Emerging pharma companies continue to rely on these vendors to provide solutions to help optimize commercial strategies.
The private equity industry will often invest in either channels or service providers and need to understand the markets, models and approaches to optimize the success of their portfolio companies. As an expert in business model assessment and development, Blue Fin Group has worked with many private equity firms when considering a new investment or working to optimize an existing portfolio company.
Meet Our Team
of Industry Experts
Blue Fin Group employees are skilled across marketing, field sales, market access, pharmacy and distribution, pricing and policy and patient services. We have a perfect mix of scientists, healthcare professionals and business leaders skilled in professional management consulting. We consult because we want to help as many pharmaceutical companies as possible bring science to market in order for patients to have affordable access.
Learn More
